James E. Talmadge
Throughout his career, Dr. James E. Talmadge has focused his research on the translational and clinical development of immune therapeutic. This focus was initiated at NCI-FCRF (9 years) where he directed the Preclinical Screening Laboratory for the Biological Response Modifiers Laboratory. These efforts continued for five years at SmithKline with a focus on cytokines and anti-inflammatory drug development. Since 1990, a greater focus on clinical studies has been undertaken at the University of Nebraska Medical Center (UNMC), focusing on stem cell transplantation, immune recovery post transplant, and clinical manipulation of immunity in association with neoplastic disease. This includes experience in T-cell, DC, and MDSC identification, function, phenotyping and molecular analysis. During the last 9 years the laboratory has also focused on the manufacture of cellular therapeutics and clinical trials of immune intervention in cancer patients. In addition, Dr. Talmadge is currently Editor-in Chief of Elsevier’s journal, International Immunopharmacology.
Abstracts this author is presenting: